Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 6/20 | 0.47 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.47 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.47 |
| ▸ | CDC42 | P60953 | 1/20 | 0.47 |
| ▸ | RAC1 | P63000 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13730948 | 0.84 | TSHR (0.56) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL14598846 | 0.84 | TDP1 (0.57) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL15929026 | 0.81 | EGFR (0.34) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL219372 | 0.80 | TDP1 (0.53) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL5498892 | 0.79 | FAAH (0.54) | TSHRLMNAMAPTCYP2C9PTGS2 | |
| SCHEMBL19719468 | 0.78 | PTGS2 (0.60) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL15929219 | 0.78 | BCHE (0.44) | — | |
| SCHEMBL219472 | 0.78 | TDP1 (0.50) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL18818204 | 0.77 | PTGS2 (0.68) | TDP1L3MBTL1TSHRLMNAMAPT | |
| SCHEMBL4435969 | 0.77 | TDP1 (0.47) | TDP1L3MBTL1TSHRLMNAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | claimed |
| EP-1492543-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | Nicox S.A. (FR) | 2005-01-05 | — | — | EP | claimed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | claimed |
| WO-2003084550-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | NICOX S.A. (FR) | 2003-10-16 | — | — | WO | claimed |
| US-7629368-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2009-12-08 | — | — | US | disclosed |
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2009-03-19 | — | — | US | disclosed |
| US-7465803-B2 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. | 2008-08-14 | — | — | US | disclosed |
| US-20070010458-A1 | Drugs for the arthritis treatment | NICOX S.A. (FR) | 2007-01-11 | — | — | US | disclosed |
| EP-1492543-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | Nicox S.A. (FR) | 2005-01-05 | — | — | EP | disclosed |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | NICOX S.A. (FR) | 2004-02-05 | — | — | US | disclosed |
| WO-2003084550-A1 | DRUGS FOR THE ARTHRITIS TREATMENT | NICOX S.A. (FR) | 2003-10-16 | — | — | WO | disclosed |
| EP-1339665-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | Nicox S.A. (FR) | 2003-09-03 | — | — | EP | disclosed |
| WO-2002030866-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NICOX S.A. (FR) | 2002-04-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090075952-A1 | NITRODERVIATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR0B1, NOX1 | TDP1 2375/4885L3MBTL1 1936/4885TSHR 3288/4885 |
| US-20080194651-A1 | NITRODERIVATIVES AS DRUGS FOR DISEASES HAVING AN INFLAMMATORY BASIS | NR3C1, NR2E1, CYP2E1 | TDP1 2459/4885L3MBTL1 1667/4885TSHR 1828/4885 |
| US-20040023933-A1 | Nitroderivatives as drugs for diseases having an inflammatory basis | TPMT, NOX1, CBR1 | TDP1 987/4885L3MBTL1 1568/4885TSHR 599/4885 |
| US-20070010458-A1 | Drugs for the arthritis treatment | PTGS1, ADORA2B, PTGS2 | TDP1 4214/4885L3MBTL1 3438/4885TSHR 2942/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.